CRISPR 2.0 Breakthroughs: Real Patients, Real Cures in 2025
CRISPR 2.0 technologies like prime and base editing have achieved error rates as low as 1 in 543, enabling FDA-approved cures for sickle cell and beta thalassemia. While costs remain high at $2 million per treatment, the one-time cure model promises to transform medicine for hundreds of inherited diseases.
